CMTA announced $523,000 in funding for four research projects focused on solving one of the biggest challenges in CMT treatment development: delivering therapies to peripheral nerve cells. By investing in genome-editing transport, blood-nerve barrier crossing, Schwann cell targeting, and nanoparticle systems, CMTA is working to ensure treatments can reach the cells where they are needed.
Particles on a Mission: Can Nanoparticles Solve One of CMT’s Largest Hurdles?
Can nanoparticles solve one of CMT’s largest hurdles? A team in Cyprus is testing nanoparticle “mail carriers” designed to deliver genetic therapies directly into Schwann cells.
Nanoparticle-Based Gene Delivery to Schwann Cells for Treating CMT Disease
With joint funding of $299,992 from CMTA and the Muscular Dystrophy Association (MDA), researchers at...
MDA, CMTA Announce Grant for Collaborative Non-Viral Gene Therapy Research on CMT1X
CMTA and MDA announced a joint three-year study evaluating a nanoparticle delivery approach for CMTX1. The project will test nanoparticle-based delivery of a therapeutic gene to Schwann cells as a potential treatment strategy.
Schwann Cell-Targeted Gene Therapy Approaches to Treat CMT1A and Other Demyelinating Neuropathies
With CMTA support of over $160,000, an international team of researchers is developing genetic therapy...
CMTX1 Biomarkers and Outcome Measures
With CMTA support of $529,971, an international team of researchers from the Inherited Neuropathy Consortium,...
